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Background: Catalase (CAT) breaks down H2O2 into H2O and O2 to protects cells from oxidative damage. However,
its translational potential is limited because exogenous CAT cannot enter living cells automatically. This study is
aimed to investigate if PEP-1-CAT fusion protein can effectively protect cardiomyocytes from oxidative stress due to
hypoxia/reoxygenation (H/R)-induced injury.
Methods: H9c2 cardomyocytes were pretreated with catalase (CAT) or PEP-1-CAT fusion protein followed by
culturing in a hypoxia and re-oxygenation condition. Cell apoptosis were measured by Annexin V and PI double
staining and Flow cytometry. Intracellular superoxide anion level was determined, and mitochondrial membrane
potential was measured. Expression of apoptosis-related proteins including Bcl-2, Bax, Caspase-3, PARP, p38 and
phospho-p38 was analyzed by western blotting.
Results: PEP-1-CAT protected H9c2 from H/R-induced morphological alteration and reduced the release of lactate
dehydrogenase (LDH) and malondialdehyde content. Superoxide anion production was also decreased. In addition, PEP-
1-CAT inhibited H9c2 apoptosis and blocked the expression of apoptosis stimulator Bax while increased the expression of
Bcl-2, leading to an increased mitochondrial membrane potential. Mechanistically, PEP-1-CAT inhibited p38 MAPK while
activating PI3K/Akt and Erk1/2 signaling pathways, resulting in blockade of Bcl2/Bax/mitochondrial apoptotic pathway.
Conclusion: Our study has revealed a novel mechanism by which PEP-1-CAT protects cardiomyocyte from
H/R-induced injury. PEP-1-CAT blocks Bcl2/Bax/mitochondrial apoptotic pathway by inhibiting p38 MAPK while activating
PI3K/Akt and Erk1/2 signaling pathways.
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Myocardial ischemia and reperfusion generate a large
amount of reactive oxygen species (ROS) in cardiom-
yocytes subject to injury. ROS assaults intracellular organ-
elles, cell membranes, and biological macromolecules
including nucleic acid, protein, and lipid, resulting in oxi-
dative stress and cell apoptosis [1,2]. Catalase (CAT) is one
of essential enzymes metabolizing oxygen free radical via
breakdown of H2O2 into H2O and O2, and thus protects* Correspondence: rywjn@vip.163.com
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reproduction in any medium, provided the orcells from oxidative damage. However, exogenous CAT
does not enter living cells automatically because of its poor
permeability and cell membrane selectivity. Its translational
value in protecting cells from oxidative stress damage,
therefore, is very limited.
A great deal of efforts have been made to deliver full-
length proteins into mammalian cells. Morris Group
has designed a new type of PEP-1 peptide carrier
(KETWWETWWTEWSQPKKKRKV) that enables the
entering of large proteins into living cells [3]. In fact,
several laboratories have successfully delivered full-
length PEP-1 fusion proteins into cultured cells and
nervous system by using this PEP-1 peptide carrier, includ-
ing EGFP, β-Gal, antibodies, cyclophilin A, and human
copper chaperone for Cu, Zn-SOD1 and CAT [4-7]. OurLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sion proteins can be transduced into myocardium and
protect against myocardial injury induced by ischemia-
reperfusion in rats [8].
Cardiomyocyte apoptosis is an inevitable process dur-
ing myocardial ischemia-reperfusion-induced injury [9].
We have previously reported an anti-apoptotic effect of
PEP-1-CAT on H9c2 cardiomyocytes [10]. However, de-
tailed mechanisms underlying the effect of PEP-1-CAT
on H/R-induced H9c2 remain unknown. In the present
study, we used the hypoxia-reoxygenation (H/R)-induced
apoptosis model to investigate the mechanisms under-
lying the anti-apoptotic effect of PEP-1-CAT in H9c2
cells. H/R is a classic in vitro model mimicking myocar-
dial ischemia-reperfusion injury in vivo. We found that
PEP-1-CAT protected H9c2 from H/R-induced injury
through blocking p38 MAPK activity and activating
PI3K/Akt and Erk1/2 activity, which resulted in a block-
ade of Bax/Bcl-2/mitochondria apoptotic pathway and
thus a reduction of cardiomyocyte apoptosis.
Materials and methods
Generation of biologically active PEP-1-CAT fusion protein
PEP-1-CAT fusion protein was isolated and purified as
described by our laboratory previously [11]. Briefly, two
prokaryotic expression plasmids for CAT and PEP-1-
CAT were constructed using TA-cloning method. Both
recombinant proteins were tagged with six histidine resi-
dues (His-tag) at the amino terminus. The two proteins
were expressed and purified separately as described [11].
Cell culture
H9c2 cells were cultured in Dulbecco’s modified Eagle’s
medium(DMEM,Invitrogen) with 5 g/L glucose supple-
mented with 15% (v/v) fetal bovine serum (FBS, Hangzhou
sijiqing Biological Engineering Materials Co., Ltd., China).
Cells were routinely grown to subconfluency (>90% by vis-
ual estimate) in 75 cm2 flasks at 37°C in a humidified at-
mosphere with 5% CO2 prior to passage and seeding for
experiments. To observe the morphological alteration,
H9c2 cells were grown on cover slips and observed using
a microscope (Nikon, Japan). To examine the aberrant
nuclei in apoptotic cells, H9c2 cells were stained with 4,6-
Diamidino-2-phenylinole (DAPI), and the nuclei were
observed using a fluorescent microscope.
Immunocytochemistry staining
H9c2 cells were grown to confluence in a 24-well plate
and treated with purified PEP-1-CAT (2 μM) or CAT
(2 μM). 6 h later, cells were washed twice with 1 × PBS
and fixed with 4% paraformaldehyde for 15 min at
room temperature. Immunocytochemistry staining was
performed by using rabbit anti-Hisprobe (diluted 1:200)
(Santa Cruz Biotechnology, USA) and mouse anti-Troponin T antibodies (diluted 1:200) (Santa Cruz Bio-
technology, USA). Cells were then incubated with tetra-
ethyl rhodamine isothiocyanate (TRITC)-conjugated rat
anti-rabbit Ig G (diluted 1:250) and fluorescein isothio-
cyanate (FITC)-conjugated goat anti-mouse Ig G (diluted
1:250) at 25°C for 1 h. After washing for 3 times with
PBS, cells were incubated with DAPI (Sigma, USA) for
10 min. The immunostained cells were observed with a
fluorescent microscope (Nikon, Japan).
Hypoxia-reoxygenation of H9c2 Cells
H9c2 cells were pretreated with or without PEP-1-CAT
(2 μM) in low serum media (2% FBS) for 6 h followed by
culturing in a low-oxygen condition (95% N2 + 5% CO2)
for 21 h in a humidified hypoxia chamber (Stem Cell
Technology, USA). After hypoxia incubation, the medium
were replaced, and the cells were exposed to normal-
oxygen condition (95% air + 5% CO2) for reoxygenation
for 6 h [12]. Control cells were cultured in normoxic con-
ditions. The supernatant and cells were collected separ-
ately for further analysis.
Measurement of lactate dehydrogenase (LDH) and
malondialdehy (MDA) levels
H9c2 cells were treated with PEP-1-CAT, harvested and
lysed as previously described LDH release and MDA con-
tent were measured using commercial kits (JianCheng
Bioengineering Institute, China).
Superoxide anion production in H9c2
H9c2 cells were grown to confluence in a 24-well plate
followed by H/R with CAT or PEP-1-CAT treatment.
Cells were then split and cultured on cover slips and in-
cubated with DHE (5 mM) (Beyotime Insitute of
Brotechnology) at 37°C for 30 min. The DHE staining
detecting superoxide anion production was observed
using a fluorescent microscope (Nikon, Japan) or quanti-
fied by Flow Cytomety.
Annexin V and PI binding assay
Annexin V and PI fluorescein staining kit (Bender
MedSystems, Austria) were utilized to measure H9c2
cell apoptosis by following the manufacturer’s instruc-
tion. Briefly, 1 × 106 cells were suspended in 200 μl 1 ×
binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl,
2.5 mM CaCl2). Cells were then incubated with Annexin
V (1:20) for 3 min followed by incubation with
propidium iodide (PI, 1 mg/ml) for 15 min. Apoptosis
rate was evaluated by Flow Cytometry.
Measurement of mitochondrial membrane potential
Mitochondrial transmembrane potential was assessed
using a sensitive fluorescent dye, a lipophilic cationic
probe JC-1 (Invitrogen, USA). H9c2 cells were grown on
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lar Probes) at 37°C for 15 min. Cells were then washed
with PBS for three times and analyzed immediately with
a fluorescent microscope. Red emission indicates mem-
brane potential-dependent JC-1 aggregates in mitochon-
dria. Green fluorescence reflects the monomeric form of
JC-1 appearing in cytoplasm after mitochondrial mem-
brane depolarization.
Quantitative reverse transcription polymerase chain
reaction (qPCR)
Total RNA from H9c2 cells was extracted using TRIZOL
Reagent (Invitrogen). RNA concentration was determined
by UV spectrophotometry. qRT-PCR was performed using
Thunderbird SYBR Master Mix (TOYOBO, Japan). Pri-
mer sequences were: Bcl-2: 5′-CGA CTT TGC AGA
GAT GTC CA-3′ (forward), 5′-ATG CCG GTT CAG
GTA CTC AG-3′ (reverse); Bax: 5′- CTG CAG AGG
ATG ATT GCT GA-3′ (forward), 5′- GAT CAG CTC
GGG CAC TTT AG-3′ (reverse); β-actin: 5′-GTC CAC
CGC AAA TGC TTC TA-3′ (forward), 5′-TGC TGT
CAC CTT CAC CGT TC-3′ (reverse). qPCR was
performed on a Real-time PCR Detection System (Slan,
Hongshi) with the following cycles: 95°C for 1 min,
followed by 95°C for 15 s, 58°C for 15 s, and 72°C for
45 s for 40 cycles. β-actin expression was used as an
internal control.
Western blot analysis
Western blot was carried out to detect protein expres-
sion using following primary antibodies: rabbit anti-Bax
(Santa Cruz Biotechnology), mouse anti-Bcl-2 (Santa
Cruz Biotechnology), rabbit anti-Caspase-3 (Santa Cruz
Biotechnology), rabbit anti-PARP-1 (Santa Cruz Biotech-
nology), rabbit anti-phospho-p38 MAPK (cell signaling
technology), and rabbit anti-p38 MAPK (cell signaling
technology). The protein expression levels were visual-
ized using enhanced chemiluminescence method.
Statistical analysis
All data are expressed as means ± SEM unless indicated
otherwise. Differences among groups were determined
by ANOVA. Differences between groups were deter-
mined by Student’s t-test with P < 0.05 considered statis-
tically significant.
Results
PEP-1-CAT restored H/R-altered H9c2 cell morphology
and decreased LDH and MDA levels
PEP-1–CAT fusion proteins were successfully trans-
duced into H9c2 cells as shown by immunocytochem-
istry staining (Additional file 1: Figure S1). CAT fusion
proteins, however, were unable to be transduced into the
cells (Additional file 1: Figure S1). H/R altered H9c2 cellmorphology. H/R treatment changed the spindle-shaped
and well-organized morphology to a shrink, round and
distorted morphology. PEP-1-CAT transduction, how-
ever, almost restored the spindle-shaped morphology
seen in the untreated cells (Figure 1A).
LDH release is an indicator of cellular injury. Com-
pared to untreated cells, LDH levels were markedly in-
creased by H/R injury. CAT transduction decreased
LDH release. PEP-1-CAT transduction, however, had a
greater impact on LDH levels compared to the CAT
transduction (Figure 1B). MDA reflects cardiomyocyte
oxidative damage. H/R treatment strikingly increased
the MDA level, but PEP-1-CAT significantly decreased
the MDA level (Figure 1C).
PEP-1-CAT had a greater effect on superoxide anion
production than CAT
H/R treatment significantly increased superoxide anion
production in H9c2 cells compared to the untreated
group. CAT transduction slightly reduced superoxide
anion level. PEP-1-CAT transduction, however, signifi-
cantly inhibited the level of superoxide anion. These re-
sults demonstrated that PEP-1-CAT had a much
stronger effect than CAT on removing superoxide anion
from the injured cells (Figure 2).
PEP-1-CAT attenuated H/R-induced H9c2 cell apoptosis
Comparing to the control group, significantly more cells
underwent apoptosis as shown by the bright DAPI stain-
ing in H/R group. H/R treatment condensed the nuclei of
H9c2 cells, an indicator of apoptosis. PEP-1-CAT trans-
duction, however, restored H9c2 nuclei to the normal
morphology (Figure 3A). Quantitative analysis using Flow
Cytometry confirmed that PEP-1-CAT significantly
inhibited H/R-induced apoptosis (Figure 3B-C). PolyADP-
ribose polymerase-1 (PARP-1) is known to be involved in
DNA damage while caspase-3 is known to regulate cell
apoptosis. To determine whether PEP-1-CAT affects H/R-
induced PARP and caspase-3 cleavage, we treated cells
with H/R in the presence and absence of PEP-1-CAT and
analyzed their cleavages using anti-PARP-1 and Caspase-3
antibodies. As shown in Figure 3D, H/R induced PARP
and caspase-3 cleavage in H9c2 cells but the effects were
inhibited by PEP-1-CAT, further demonstrating that PEP-
1-CAT suppressed H/R-induced apoptosis.
PEP-1-CAT regulated the expression of apoptosis-related
proteins
To investigate the mechanism whereby PEP-1-CAT at-
tenuates H/R-induced H9c2 apoptosis, we examined the
expression of Bcl-2 and Bax. Both qRT-PCR and Western
blot analyses showed that Bcl-2 expression was mark-
edly increased in PEP-1-CAT-pretreated cells compared
to the H/R or CAT-treated group. As expected, Bax
Figure 1 PEP-1-CAT restored H/R-induced alteration of H9C2 cell morphology while inhibiting H/R-induced LDH release and MDA
production. (A) Effect of PEP-1-CAT on H9c2 cell morphology. Upper panel: cell morphology prior to H/R treatment; lower panel: cell
morphology with H/R treatment. (B) PEP-1-CAT reduced LDH levels *P<0.01 vs control (CTL); &P<0.05 vs H/R; #P<0.01 vs H/R or H/R + CAT (CAT);
n = 6. (C) PEP-1-CAT decreased MDA levels. *P<0.01 vs control (CTL);&P<0.05 vs H/R; #P<0.01 vs H/R or H/R + CAT (CAT); n = 6.
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(Figure 4A-D), suggesting that PEP-1-CAT prevented
H9c2 cells from apoptosis by increasing Bcl-2 while
inhibiting Bax expression.
PEP-1-CAT restored H/R-blocked mitochondrial
membrane potential
Untreated cells exhibited bright-staining mitochondria
that emitted red fluorescence. H/R treatment caused the
formation of monomeric JC-1, indicative of loss of mem-
brane potential. PEP-1-CAT pretreatment, however,
blocked the HR-induced formation of JC-1 monomers
(Figure 5A-B), suggesting PEP-1-CAT can restore H/R-
induced loss of mitochondrial membrane potential.
PEP-1-CAT inhibited H/R-induced H9c2 apoptosis through
regulating multiple signaling pathways
Previous studies have shown that apoptosis is medi-
ated by multiple signaling pathways or protein factorsincluding PI3K/Akt, p38 and Erk1/2 MAPK, etc.
[13,14]. To determine which pathways are involved in
PEP-1-CAT-mediated protection of H/R-injured H9c2
cells, we treated H9c2 with specific inhibitors for each
individual pathways. We found that PI3K/Akt and
Erk1/2 signaling pathways were essential for mediating
PEP-1-CAT inhibition of H/R-induced apoptosis be-
cause PI3K/Akt inhibitor wortmannin, PI3K siRNA,
Erk1/2 inhibitor PD98059, or Erk1 siRNA blocked PEP-1-
CAT-induced reduction of H9c2 apoptosis (Figure 6A-B).
p38 MAPK appeared to be also important for PEP-
1-CAT function. Although p38 MAPK inhibitor did
not reverse PEP-1-CAT-mediated decrease of H9c2
apoptosis (Figure 6A-B), PEP-1-CAT transduction
inhibited p38 phosphorylation (Figure 7), suggesting
that PEP-1-CAT blocks p38 signaling. These results
demonstrated that PEP-1-CAT attenuated p38 sig-
naling while enhancing PI3K and Erk1/2 MAPK
signaling.
Figure 2 PEP-1-CAT inhibited H/R-induced superoxide anion production. (A) Superoxide anion production was observed using a fluorescent
microscope. (B) Superoxide anion production was quantified by Flow Cytometry (n = 6). *P<0.01 vs control (CTL); &P<0.05 vs H/R; #P<0.05 vs H/R
or H/R + CAT (CAT); n = 4.
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Myocardial apoptosis is a significant pathophysiological
event in myocardial ischemia-reperfusion injury [9]. It is
widely acknowledged that intervention of myocardial
apoptosis is a very important approach to the prevention
of myocardial ischemia-reperfusion injury [15]. Reperfu-
sion causes myocardium to produce a large amount of
ROS including superoxide anion (O2
- ⋅), hydroxyl radicalFigure 3 PEP-1-CAT inhibited H/R-induced H9c2 cell apoptosis. H9c2 c
normoxia environment for 27 h or into hypoxia chamber for 21 h followed
staining. (B-C) H/R-induced H9c2 apoptosis rate was quantiied by Flow Cyt
H/R + CAT (CAT); n = 5. (D) PARP and caspase-3 protein expression was det(OH-), and hydrogen peroxide (H2O2), etc [16]. CAT,
one of most important enzymes, can protect cells from
oxidative damage. But its potential to be used to protect
myocardium from H/R-induced injury is hindered by the
poor permeability and the selectivity of cell membrane.
By fusing CAT with a PEP-1 peptide, we were able to
efficiently transduce PEP-1-CAT into H9c2 cells and
protect myocardium from H/R-induced injury [10]. Theells were pretreated with CAT or PEP-1-CAT for 6 h and placed into
by 6 h reoxygenation. (A) Cell apoptosis was detected by DAPI
ometry. *P<0.01 vs control (CTL);&P<0.05 vs H/R; #P<0.01 vs H/R or
ected by western blot.
Figure 4 PEP-1-CAT regulated Bcl-2 and Bax expression. (A) Bcl2 and Bax mRNA expression was detected by qRT-PCR and normalized to β-
actin. *P<0.01 vs control (CTL); &P<0.05 vs H/R; #P<0.05 vs H/R or H/R + CAT (CAT); n = 3. (B) Bcl2 and Bax protein expression was detected by
western blot. (C) Normalization of Bcl2 and Bax expression to α-Tubulin. *P<0.01 vs control (CTL); &P<0.05 vs H/R; #P<0.05 vs. H/R or H/R + CAT
(CAT); n = 4. (D) Bcl2/Bax ratio. *P<0.01 vs control (CTL); &P<0.05 vs H/R; #P<0.05 vs H/R or H/R + CAT (CAT); n = 4.
Figure 5 PEP-1-CAT restored H/R-induced reduction of mitochondrial membrane potential. (A) Mitochondrial transmembrane potential
was assessed by the lipophilic cationic probe JC-1. Red signal indicates JC-1 aggregates in mitochondria. Green signal shows cytosolic JC-1
monomers indicative of the loss of mitochondrial membrane potential. (B) Quantitative analysis of membrane potential in (A). *P < 0.05 vs control
(CTL); &P < 0.05 vs H/R; #P<0.05 vs H/R or H/R + CAT (CAT) group; n = 3.
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Figure 6 PEP-1-CAT inhibited H/R-induced H9c2 apoptosis via p38, PI3K and Erk1/2 MAPK signaling pathways. (A) H9c2 apoptosis was
assessed by Flow Cytometry. (B) Quantification of H9c2 apoptosis rate. *P<0.01 vs CTL; @P<0.01 vs H/R group; $P<0.01 vs H/R or PEP-1-CAT-
treated group; &P<0.05 vs PEP-1-CAT-treated group; #P<0.05 vs PEP-1-CAT-treated group; n = 5.
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identifying novel mechanisms underlying PEP-1-CAT
function in protecting cardiomyoctyes. We have found
that PEP-1-CAT protects H/R-induced injury of H9c2
cells by restoring H/R-induced alteration of H9c2
morphology, inhibiting H/R-induced production of
O2⋅, and blocking LDH release and MDA production,Figure 7 PEP-1-CAT inhibited p38 phosphorylation. (A) Western blot an
analysis of p38 phosphorylation by normalizing to total p38. $P<0.01 vs CTL; *the two indicators for hypoxia-reoxygenation injury
[17,18].
ROS causes damages to intracellular macromolecules
such as DNA breakage and lipid membrane peroxidation,
leading to cell apoptosis [19]. Our data demonstrate that
PEP-1-CAT blocks H/R-induced H9c2 apoptosis by regu-
lating mitochondria-related apoptotic pathways. Recentalysis showing PEP-1-CAT inhibited p38 phosphorylation. (B) Quantitative
P<0.05 vs H/R group; #P<0.01 vs PEP -1-CAT-treated group; n = 4.
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to produce a high level of ROS [20,21]. Excessive ROS
damages mitochondria, opens its permeability transition
pore (PTP) and thus induces mitochondrial permeability
transition (MPT), leading to mitochondrial depolarization
and outer membrane rupture, which causes cell apoptosis
or death [22,23]. Our studies indicate that H/R induces a
decreased mitochondrial membrane potential, suggesting
an impairment of mitochondria function. PEP-1-CAT
transduction, however, restores mitochondrial membrane
potential. These data demonstrate that PEP-1-CAT
protects H9c2 cells from H/R-induced apoptosis by
maintaining mitochondria membrane integrity and func-
tion of cardiomyocytes. Moreover, previous studies indi-
cate that Bcl-2 family is upregulated during the opening of
PTP [24]. Our results demonstrate that PEP-1-CAT regu-
lates the expression of Bcl-2 family. PEP-1-CAT signifi-
cantly increases Bcl-2 while decreasing Bax protein levels
that are altered by H/R injury.
PEP-1-CAT prevents cardiomyocyte from H/R-induced
injury by regulating multiple signaling pathways. Although
a number of signaling pathways are involved in H/R-
induced myocardial injury and apoptosis, PEP-1-CAT pro-
tects cardiomyocytes through down-regulation of p38
MAPK and activation of PI3K and Erk1/2 signaling path-
ways. PEP-1-CAT transduction inhibits p38 MAPK phos-
phorylation, suggesting that p38 MAPK mediates, at least
in part, the function of PEP-1-CAT. Blockade of PI3K
and Erk1/2 signaling significantly attenuates PEP-1-CAT-
mediated reduction of H9c2 apoptosis, indicating that
PI3K and Erk1/2 signaling pathways are essential for PEP-
1-CAT activity in protecting cardiomocytes.
In summary, PEP-1-CAT transduction efficiently pro-
tects cardiomyocyte from H/R-induced apoptosis by
blocking ROS production in mitochondria, which main-
tains mitochondria membrane integrity and inhibits the
activation of Bcl2/Bax apoptotic pathway. Moreover, PEP-
1-CAT blocks cardiomyocyte apoptosis by blocking p38
MAPK while activating PI3K and Erk1/2 MAPK signaling
pathways. How these signaling pathways interact with
each other in mediating PEP-1-CAT function will be a in-
teresting subject for future study. Nevertheless, our study
provides novel information and rationale for developing
PEP-1-CAT as a therapeutic agent for treating or
preventing myocardial ischemia-reperfusion injury.Additional file
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